Is your Heart Failure treatment plan missing an essential piece?
The Cardio-Kidney Metabolic (CKM) burden in heart failure
Diabetic kidney disease (DKD) and Heart Failure (HF) are interrelated, progressive conditions driven by a shared cardiorenal-metabolic dysfunction that can lead to multisystem dysfunction through shared inflammatory and fibrotic pathways.
Adapted from Vijay K et al, 2022
- Symptomatic chronic heart failure with left ventricular ejection fraction(LVEF) ≥40% in adults.
- Chronic Kidney Disease (stages 3 and 4 with albuminuria) associated with Type 2 Diabetes in adult patients.
The scale of unmet needs in HF (LVEF ≥40%) and DKD
Almost 400,000 adults are thought to be living with HF LVEF ≥40% in the UK
21%
with symptomatic outpatient HF events escalate to HF hospitalisation or CV death*
1 in 5
are rehospitalised within 30 days of discharge
Chronic Kidney Disease (CKD) develops in ~40% of those with T2D
28%
of people receiving kidney replacement therapy have diabetic kidney disease (DKD)
~3x higher risk
of CV-related deaths in patients with CKD and T2D vs T2D alone
* Based on patients with HF LVEF ≥40% in a pivotal SGLT2i trial whose first presentation manifested as an outpatients oral diuretic intensification (n=789).
Kerendia blocks mineralocorticoid receptor (MR) activation - a key driver of HF (LVEF ≥40%) and DKD
Blocking MR overactivation
Affecting key disease drivers
Slowing disease progression
Kerendia is a nonsteroidal mineralocorticoid receptor antagonist (nsMRA) that is clinically and pharmacologically distinct from steroidal MRAs (sMRAs)
Featuring:
- Professor John McMurray(Professor of Cardiology (Cardiology & Metabolic Health), School of Cardiovascular and Metabolic Health)
- Professor Richard Hobbs(Mercian Professor of Primary Care, University of Oxford)
Prescribing information for Kerendia®▼(finerenone)
Abbreviations
PP-KER-GB-0917 | April 2026